Trial Profile
Six courses of fluorouracil + epirubicin + cyclophosphamide (FEC100) versus three courses of FEC100 followed by three courses of docetaxel in women with localised, resectable, non-pretreated unilateral breast cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Early breast cancer
- Focus Therapeutic Use
- 01 Jun 2023 Results published in the Breast Cancer Research and Treatment
- 01 Jun 2023 Results of a 10-year follow-up analysis published in the Breast Cancer Research and Treatment
- 01 Jul 2012 Eight-year follow-up results published in Oncologist.